Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Background: While there is a clear consensus for defining radioiodine-refractory differentiated thyroid cancer (RR-DTC), it is unknown whether these criteria are equally valid for determining when radioiodine (RAI) therapy is no longer beneficial and systemic treatment should be considered. Lenvatin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thyroid
Hlavní autoři: Kiyota, Naomi, Robinson, Bruce, Shah, Manisha, Hoff, Ana O., Taylor, Matthew H., Li, Di, Dutcus, Corina E., Lee, Eun Kyung, Kim, Sung-Bae, Tahara, Makoto
Médium: Artigo
Jazyk:Inglês
Vydáno: Mary Ann Liebert, Inc. 2017
Témata:
Thyroid Cancer and Nodules
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5646742/
https://ncbi.nlm.nih.gov/pubmed/28665259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2016.0549
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky